[Malignant melanoma : Current status]. - Wikidata - wikimedia - TriplyDB

[Malignant melanoma : Current status].

[Malignant melanoma : Current status].

http://www.wikidata.org/entity/Q40113867

about

[Light at the end of the tunnel].Sinomenine inhibits the growth of melanoma by enhancement of autophagy via PI3K/AKT/mTOR inhibition

P2860

Q49921360-F066F318-3FB5-4ACB-89B8-A8B9E930210A Q58799263-59E6C7E9-E242-491C-A151-B626C923C2B0

P2860

[Malignant melanoma : Current status].

http://www.wikidata.org/entity/Q40113867

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

[Malignant melanoma : Current status].

@en

type

label

[Malignant melanoma : Current status].

@en

prefLabel

[Malignant melanoma : Current status].

@en

P1433

Q40113867-6D02B69C-2F1B-4A22-BD8E-A9DE8644DD39

P1476

Q40113867-DC22E5FC-4C8E-416A-8014-395DD44E4E44

P2093

Q40113867-3D0F7797-4FFC-46AE-81F5-A5E78478A831

Q40113867-4DFECA37-5B84-45BA-BB2B-EE6E5BC8346A

Q40113867-75DD592C-5DE2-48CB-AA99-8B96F05B2535

Q40113867-D64DF016-0371-447A-8EE2-CB13022069D1

P2860

Q40113867-040E46A7-C9B9-47CE-8376-C2BC9F9FBE79

Q40113867-1A240540-3627-4C1D-BB37-804A196E2FC6

Q40113867-1DC76DB5-E04C-40D4-B29F-3D1B6FFB6EE5

Q40113867-2715B9B0-BA08-47E3-8271-82E699C802C0

Q40113867-3C6B87A1-284F-4D0F-A5DF-E5D8766E13FA

Q40113867-3FEEBD43-6164-4CAB-866D-0F58DCBFF578

Q40113867-4822E88D-EF4E-496F-B75F-FDFDA62C98A3

Q40113867-4B42747A-FBA4-46A8-8796-6E215D022342

Q40113867-51216126-7B8D-4475-8A29-78FF7C7975B0

Q40113867-52108C2F-878D-4490-91C4-B6E0167A15E2

P2888

Q40113867-14E447D1-018E-44ED-9D7B-72093FD69796

P304

Q40113867-EBDDD712-00DC-4C60-8F1C-14107E000578

P31

Q40113867-1726F1E2-14BC-4008-8AB2-E6E25601233A

P356

Q40113867-12B82972-BB53-4184-8940-DB2E1EF51A40

P407

Q40113867-BBB33659-419C-4A25-9FC7-4581843E5DFF

P433

Q40113867-C3E30BD1-1399-4719-A097-927A3337E2E0

P478

Q40113867-8646A974-3CDB-4B71-AEAB-98F2DE9384BB

P50

Q40113867-3FD1B86B-2378-4E4C-AFEA-6F383EF5774C

P577

Q40113867-B629E529-60E1-4CC9-B264-50C9815EFA86

P698

Q40113867-3824F10C-2782-4E8F-A2C0-049DEB9517CB

P356

S00117-017-0281-4

P1433

P1476

[Malignant melanoma : Current status]

@en

P2093

A Enk

http://www.w3.org/2001/XMLSchema#string

J C Hassel

http://www.w3.org/2001/XMLSchema#string

J K Winkler

http://www.w3.org/2001/XMLSchema#string

K Buder-Bakhaya

http://www.w3.org/2001/XMLSchema#string

P2860

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Signatures of mutational processes in human cancer

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Immunologic correlates of the abscopal effect in a patient with melanoma

P2888

s00117-017-0281-4

P304

814-821

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00117-017-0281-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

Antonia Dimitrakopoulou-Strauss

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28730266

http://www.w3.org/2001/XMLSchema#string